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Trastuzumab (Herceptin) has improved therapy of breast cancer. Only patients overexpressing ERBB2 are treated with trastuzumab,
whereas its use in tumours without ERBB2 expression is useless. This led to the concept that the subgroup of trastuzumab-sensitive
tumours is ‘ERBB2-dependent’, meaning that ERBB2 signalling is indispensable for growth of these tumours. We used a mouse model
that allows anhydrotetracycline (ATc)-controlled downregulation of ERBB2 in tumour tissue. ERBB2 mRNA and protein expression
were downregulated below detection limit leading to a macroscopically complete tumour remission within 14 days. Tumour
remission was accompanied by a strong decrease in proliferation, a moderate increase in apoptosis, as well as dephosphorylation of
ERK1/2 and AKT/PKB. These data clearly indicate ERBB2 dependence. Therefore, a high sensitivity to trastuzumab may be suspected.
Surprisingly, trastuzumab caused a much weaker effect compared to ATc-induced ERBB2 downregulation, although a decrease in
ERBB2 membrane localisation was induced. Only a slight decrease in proliferation and a weak transient increase in apoptosis were
observed. Interestingly, tumours responded to trastuzumab by a sharp fivefold increase in phosphorylated AKT/PKB as well as a 3.5-
and 5.3-fold increase in AKT1 and AKT2 mRNA levels, respectively. In conclusion, ‘ERBB2 dependence’ is not sufficient to define
trastuzumab-responsive tumours. The suboptimal effect of trastuzumab compared to the maximally possible effect induced by ATc
demonstrates a high potential for improved ERBB2 blocking therapies.
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Since its discovery as a human oncogene, ERBB2 has been
intensively investigated as a target for therapeutic intervention
(review: (Ullrich and Schlessinger, 1990; Zwick et al, 2000)).
Among a variety of strategies two have shown the most promising
results. One approach utilises small molecule inhibitors targeting
the kinase domain (review: (Fischer et al, 2003)). The second
approach is the generation of antibodies directed against the
extracellular domain of ERBB2 (Hudziak et al, 1989; Fendly et al,
1990; Scott et al, 1991). Trastuzumab is a humanised monoclonal
antibody that binds to the membrane adjacent cysteine rich part of
the extracellular domain of ERBB2 (Cho et al, 2003). Several
distinct mechanisms are responsible for its antitumour activity: (i)
internalisation of ERBB2 from the cell surface (Wartlick et al,
2004), (ii) blockade of metalloprotease-induced cleavage of ERBB2
generating a soluble extracellular domain and a kinase active
intracellular fragment (Molina et al, 2001) and (iii) antibody-
dependent cytotoxicity mediated by the Fc portion of trastuzumab
(Clynes et al, 2000).
Trastuzumab (Herceptin) has significantly improved therapy of
breast cancer. In the 1990s trastuzumab was shown to induce
tumour remission in patients with metastatic breast cancer after
failure of conventional chemotherapy (reviewed by Baselga, 2006).
In subsequent studies trastuzumab was found to improve survival
when combined with chemotherapy or given sequentially after
chemotherapy (Slamon et al, 2001; Piccart-Gebhart et al, 2005;
Romond et al, 2005). In large studies combining more than 14000
patients the addition of trastuzumab to systemic chemotherapy
resulted in a 52% reduction of recurrence 4 years after surgery
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s(reviewed by Tsuda, 2006). Trastuzumab clearly enhanced the
activity of anthracyclines, taxanes and platinum compounds.
In recent years many scientists have concentrated on the
question why some patients respond to trastuzumab whereas
others do not (Cappuzzo et al, 2006; Chon et al, 2006; Menendez
et al, 2006; Tseng et al, 2006). A correlation between the extent of
ERBB2 expression determined by immunohistochemistry or FISH
and the clinical response has been observed in several studies
(Vogel et al, 2002; Mass et al, 2005; Tsuda, 2006). Women whose
breast tumours stain 3þ for ERBB2 (meaning that strong
complete membrane staining is seen in more than 10% of tumour
cells) are most likely to respond to trastuzumab (Vogel et al, 2002;
Mass et al, 2005) (reviewed by Tokunaga et al, 2006). The activity
of trastuzumab in breast carcinomas overexpressing ERBB2 has
contributed to the concept that certain tumours are ‘oncogene
dependent’ (Weinstein, 2002; Baselga, 2006; Hengstler et al, 2006).
This concept suggests that trastuzumab should be used only for the
subset of tumours whose growth depends on the oncogenic signal
of ERBB2. In the present study, we made the surprising
observation that a ‘ERBB2-dependent’ tumour can be completely
resistant to trastuzumab. We used NIH 3T3 cells expressing ERBB2
by the TET-OFF system (Schiffer et al, 2003). These cells form
rapidly growing tumours in nude mice. Switching-off ERBB2
expression by tetracycline administration causes a rapid and
complete tumour remission, demonstrating a high degree of
‘ERBB2 dependence’. In the same tumours trastuzumab caused
translocation of ERBB2 from the membrane to the cytoplasm but
tumour growth was only slightly delayed. Our study demonstrates
that cells can be ERBB2 dependent but nevertheless resistant to
trastuzumab.
MATERIALS AND METHODS
Cells with ERBB2 expression under control of tTA
NIH3T3 is an immortalised cell line originally derived from mouse
embryo fibroblasts and was obtained from ATCC (American Type
Culture Collection). Wild type NIH3T3 and its derivatives were
grown in Dulbecco’s modified Eagle’s medium (DMEM, PAN;
Aidenbach, Germany) supplemented with 10% fetal bovine serum
(tetracycline free, Biochrom AG, Berlin, Germany) and 1%
penicillin–streptomycin (PAN). Cells were cultured at 371Ci n
5% CO2 humidified air (Schiffer et al, 2003; Hausherr et al, 2006).
Conditional expression of ERBB2 was achieved using the TET-OFF
system originally described by Gossen and Bujard (Gossen and
Bujard, 1992). Briefly, wild type NIH3T3 cells were co-transfected
with three vectors (pUHD 15-1, pTBC1 Hygro
s and pTBC ERBB2/
SEAP) as described by Baasner et al (1996) resulting in a cell line
termed NIH3T3-HER2. Cotransfection resulted in tetracycline
controlled ERBB2 expression: exposure of cells to anhydrotetracy-
cline hydrochloride (ATc) lead to a complete down regulation of
ERBB2 (Schiffer et al, 2003). Selection for stable transfection was
achieved by adding 125mgml
 1 hygromycin B (Sigma-Aldrich,
Schnelldorf, Germany) to the cell culture medium. Expansion of
NIH3T3-HER2 cells was performed in the presence of hygromycin
B. In contrast, all experiments including exposure to ATc were
done in the absence of hygromycin B.
Induction of ERBB2-dependent tumours and
determination of tumour growth
NIH3T3-HER2 cells (7 10
6) were subcutaneously injected into
the dorsal skin of 3- to 4-weeks-old male nude mice (cd nu /nu )
(Charles River, Sulzfeld, Germany). Animals were housed under
specific pathogen-free conditions. Eight to ten days after injection
of the NIH3T3-HER2 cells, small tumours with a mean diameter of
0.5cm became visible. The tumour diameter was measured using a
calibre rule. Maximal and minimal diameters of the tumours were
determined. The mean value of the maximal and minimal
diameters was defined as the mean diameter. Tumour volume
(V) was calculated by the formula: V¼abb/2, whereby ‘a’
represents the minimal and ‘b’ represents the maximal tumour
diameter. A complete remission was achieved, when absolutely no
tumour volume was macroscopically visible. Anhydrotetracycline
was administered to the mice by subcutaneous (s.c.) injection.
Experiments reported here were approved by the local Ethical
Committee, in accordance with the Declaration of Helsinki and
National Institutes of Health guidelines.
Western blot analysis
Preparation of tumour tissue Mice were killed by cervical
dislocation and tumours were isolated, shock frozen in liquid
nitrogen-cooled 2-methylbutane and stored at  801C. To pulverise
the tumour tissue a mortar and pestle on dry ice was used. Then
the samples were lysed in solubilisation buffer by sonification (10
strokes, three times; Labsonic U, B. Braun Medical AG, Emmen-
bru ¨cke, Germany) on ice. To remove cell debris, the suspensions
were centrifuged at 18000g for 10min. The supernatants were
collected and protein concentration was estimated by the BCA
assay, according to the manufacturer’s protocol. The Lyses buffer
which was used, contained 25mM Tris-phosphate, 2mM EDTA
(ethylenediamine tetra-acetic acid), 2mM DTT (1,4-dithio-threi-
tol), 10% glycerol and 1% Triton-X-100 (pH 8). The solubilisation
buffer was supplemented with 1% of a commercially available
protease inhibitor cocktail (Sigma) containing 4-(2-aminoethyl)-
benzenesulphonyl fluoride (AEBSF), pepstatin A, trans-epoxy
succinyl-L-leucylamido(4-guanidino)butane (E-64), bestatin, leu-
peptin and aprotinin.
Preparation of mitochondrial and cytosolic extracts for cytochrome
c detection Frozen tumour tissue specimens were put into ice-
cold homogenising buffer (250nmoll
 1 sucrose, 10mmoll
 1
HEPES, 1mmoll
 1 EDTA, 1mmoll
 1 EGTA, 5mmoll
 1 DTT,
2mgml
 1 aprotinin and 2mgml
 1 leupeptin). After homogenisa-
tion with a Potter-Elvehjem teflon-glass homogeniser (20 strokes),
the homogenates were centrifuged at 7000g for 10min, 41C.
Supernatant was collected after centrifugation at 10000g for
30min at 41C. The supernatants and the pellets were analysed by
western blotting. The supernatant represents the cytosolic fraction,
whereas the pellet contains the mitochondria.
Western blotting Total cellular protein (50mg for all analysis)
were mixed with sample buffer according to the protocol of
Laemmli (25) and resolved on a 10% (HER-2) or on a 12%
(phospho akt, akt, phospho p44/42 and p44/42 MAP kinase) SDS–
polyacrylamide gel by electrophoresis. Thereafter, proteins were
electrotransferred onto Poly Screen PVDF (polyvinylidene-difluoride)
Transfer Membranes (NEN
s Life Science, Boston, MA, USA). The
membranes were blocked with PBST (PBSþ0.1% Tween 20)
containing 10% Roti
s-Block (Roth, Karlsruhe, Germany) for 1h
and then incubated with the anti HER-2/neu for 2h at room
temperature (RT) or the anti cytochrome c, phospho akt, akt,
phospho p44/42 and p44/42 MAP kinase antibodies overnight at
41C or as a loading control with the anti b-actin antibody for
30min at RT. After washing, the membranes were incubated with
the secondary antibody, horseradish peroxidase conjugated anti-
mouse immunoglobulin for 20min or anti-rabbit immunoglobulin
for 60min at RT. The secondary antibody to detect the cytochrome
c primary antibody was incubated for 60min. After final washing,
proteins were visualised with a chemiluminescence detection
system (Western Lightningt Chemiluminescense Reagent Plus,
PerkinElmer Life Science, Boston, MA, USA) and with subsequent
exposure to an Imager System (INTAS, Go ¨ttingen, Germany). The
expression levels were quantified using GelProAnalyzer software
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s(GelProAnalyzer 4.5 for Windows 2000). For evaluation of
apoptosis the ratios of cytosolic and mitochondrial cytochrome c
were calculated. The MagicMarkt Western Standard from
Invitrogen (Invitrogen GmbH, Karlsruhe, Germany) served as an
internal protein standard. For repeated staining, individual
membranes were stripped with a buffer containing 0.76% Tris-
base, 2% SDS and 0.7% 2-mercaptoethanol adjusted with HCl to
pH 6.8 for 1h at 501C. The SDS–PAGE and the membrane (after
the last staining with antibodies) were further stained with
Coomassie blue to confirm equal amount of proteins applied in
each lane.
Origin and dilution of antibodies The monoclonal antibody
against human HER-2/neu (a 185kDa protein) was obtained from
Quartett (Berlin, Germany) and used in a dilution of 1:270. The
monoclonal antibody against mouse b-actin (a 42kDa protein)
(Sigma) was used in a dilution of 1:5000. The anti-mouse
phosphor-akt antibody (Cell Signaling) was diluted 1:200, the
anti-mouse akt antibody, the anti-mouse phosphor-p44/42anti-
body and the anti-mouse phosphor-p44/42antibody were obtained
from Cell Signaling and all were diluted 1:1000. The secondary
antibody, peroxidase-linked anti-rabbit (Cell Signalling) was used
in a dilution of 1:1000. Peroxidase-linked anti-mouse antibody,
obtained from Sigma, was used in a concentration of 1:5000 to
detect b-actin and 1:50000 to detect HER-2. The antibody against
cytochrome c (BD) was used in a dilution of 1:1000 and the
secondary antibody anti-mouse 1:2000 (Sigma). Primary and
secondary antibodies were all diluted in PBS-T containing 10%
Roti
s-Block.
Immunohistochemical detection of Ki-67 In addition to the
staining with the anti-human HER-2 antibody, the same protocol
was also performed using an anti-mouse Ki-67 antibody (Ki-67
rabbit anti-mouse, Dianova, Hamburg, Germany) diluted 1:50 in
TBS containing 5% fetal calf serum.
Immunohistochemical detection of Her-2/neu Her-2/neu was
analysed immunohistochemically in paraffin sections using the
Hercep Test
R, an FDA-approved assay for identification of tissues
overexpressing p185 Her2 (K5205 Dako, Denmark), in accordance
with the manufacturer’s protocol and scoring guidelines.
Evaluation of immunohistochemical slides Using the anti-mouse
Ki-67 antibody the percentage of Ki-67 positive tumour cells was
determined in relation to all tumour cells. For this purpose five
representative areas with vital tumour cells or tissue were
randomly selected. Evaluation was performed using an Olympus
microscope (BX-41) with 100-fold magnification. The percentage
of Ki-67 (nuclear staining) positive cells was determined
independently by two experienced investigators (MH; MW). Mean
values for all five areas were calculated. In all cases the values
obtained by both investigators differed by less than 10%. ERBB2
membrane localisation was evaluated by an experienced patholo-
gist (LCH) on blinded slides.
RESULTS
ERBB2 downregulation causes massive tumour remission
We used a mouse tumour model that allows tetracycline-controlled
expression of ERBB2. This mouse model is based on NIH3T3-
HER2 cells that conditionally express ERBB2 by the TET-OFF
system. NIH3T3-HER2 cells were injected into the dorsal skin of
nude mice to induce subcutaneously growing tumours. Untreated
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Figure 1 Influence of anhydrotetracycline (ATc) (10mgkg
 1, s.c., daily)
and trastuzumab (40mgkg
 1, ip, daily) on ERBB2 mRNA expression in
tumour tissue. Data are mean values and standard errors of 3–5 mice per
group. Mean expression level of controls corresponds to 100%.
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Figure 2 (A) Influence of anhydrotetracycline (ATc) and trastuzumab on ERBB2 protein expression levels in tumours of mice; (B) Representative
immunoblot showing ERBB2 downregulation during ATc therapy; (C) Representative immunoblot showing ERBB2 downregulation during trastuzumab
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stumours expressed relatively high levels of ERBB2 mRNA
(Figure 1) and protein (Figure 2). Immunostaining by the
HercepTest showed a strong membrane and cytoplasmic staining
(Figure 3A) corresponding to score 3þ of human breast
carcinomas (Figure 3B). As soon as the tumours reached a volume
of 1.7cm
3 mice were either treated with anhydrotetracycline (ATc,
daily i.p. injections of 10mgkg
 1 for 7 days) or with trastuzumab
(daily i.p. injections of 40mgkg
 1 for 7 days; see next paragraph).
Injection of ATc resulted in downregulation of ERBB2 mRNA
expression below detection limit within 24h (Figure 1). Similarly,
immunoblot analyses showed a decrease in ERBB2 expression
(Figure 2). After 3 days of ATc exposure ERBB2 protein expression
was no longer detectable. ATc induced downregulation of ERBB2
mRNA and protein led to a rapid reduction in tumour volume
(Figure 5). Tumour volumes decreased by 20, 48, 62, 75, 87, 89 and
92% after 1, 2, 3, 4, 5, 6 and 7 days of ATc administration,
respectively, compared to the tumour volume before therapy. The
results show that the tumour cells in our mouse model are highly
ERBB2 dependent.
Trastuzumab decreases ERBB2 membrane localisation but
causes only a slight delay in tumour growth
The influence of trastuzumab was tested under similar conditions
as described above for ATc. As soon as tumours reached a volume
of 1.7cm
3, the mice received daily i.p. injections of 40mgkg
 1
trastuzumab. In contrast to ATc administration trastuzumab did
not cause a decrease in ERBB2 mRNA (Figure 1) or protein
(Figure 2C) expression. Nevertheless, the influence of trastuzumab
could clearly be detected on a biochemical level by an alteration in
subcellular localisation of ERBB2. Before onset of trastuzumab
therapy ERBB2 showed a strong membrane and cytoplasmic
staining (Figure 3A). Six and 72h after administration of
trastuzumab membrane staining was strongly reduced (Figure 3C
and D; ). In contrast to ATc, trastuzumab caused only an initial,
weak delay of tumour progression (Figure 5). Therefore, despite
their dependence on ERBB2, NIH3T3-HER2 tumours are relatively
resistant to trastuzumab.
Trastuzumab increases Akt phosphorylation and mRNA
synthesis
Phosphorylation of Akt is known as an antiapoptotic response to
stress (Schiffer et al, 2003; Hausherr et al, 2006). Therefore, we
studied levels of phosphorylated and total Akt in tumour tissue
after administration of ATc or trastuzumab. ATc initially (3–6h
after administration) caused a slight approximately 1.8-fold
increase in phosphorylated Akt, followed by a sustained decrease
after 3 and 7 days of ATc exposure (Figure 6A). Interestingly, a
completely different scenario was observed after trastuzumab
therapy (Figure 6B). A strong 4–5-fold increase in p-Akt was
observed 1–6h after administration of trastuzumab. Later, 1–7
days after onset of trastuzumab therapy, p-Akt levels decreased
again, but still remained about 2–3-fold above levels of untreated
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Figure 3 Influence of anhydrotetracycline (ATc) and trastuzumab on
membrane localisation of ERBB2. (A) Untreated NIH3T3-HER2 tumour;
(B) positive control; (C) NIH3T3-HER2 tumour 3h after injection of
trastuzumab; (D) NIH3T3-HER2 tumour treated for 7 days with
trastuzumab; (E) NIH3T3-HER2 tumour 3h after injection of ATc; (F)
NIH3T3-HER2 tumour treated for 7 days with ATc.
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Figure 4 Influence of anhydrotetracycline (ATc) (A) and trastuzumab (B) on localisation of ERBB2. Both, anhydrotetracycline (ATc) and trastuzumab
caused a loss of ERBB2 membrane localisation. Data are mean values and s.e. of 3–5 mice per group.
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stumours. Both, ATc and trastuzumab caused a strong increase in
Akt1 and Akt2 mRNA expression (Figure 6C and D). However, the
kinetics were different in ATc- and trastuzumab-treated mice.
Following ATc-mediated ERBB2 downregulation a slow but
sustained increase in Akt mRNA expression was observed over
the entire exposure period of 7 days (Figure 6C). In contrast,
trastuzumab induced a sharp increase in Akt mRNA expression
already 1h after administration, followed by a plateau with levels
about 3–4-fold above controls. In a previous study we have
already shown a strong dephosphorylation of Erk 1/2 as a
consequence of ATc-mediated ERBB2 downregulation (Schiffer
et al, 2003). In contrast to ATc, trastuzumab did not decrease levels
of phosphorylated Erk1/2 as well as total Erk (Figure 7).
Tumour remission in relation to proliferation and
apoptosis
The fraction of Ki-67 positive nuclei was determined in tumour
tissue to study a possible influence of ATc and trastuzumab on
proliferation. Downregulation of ERBB2 by ATc led to a strong
decrease in proliferating tumour cells (Figure 8). In contrast,
trastuzumab did not decrease the fraction of Ki-67-positive nuclei.
Therefore, the difference in tumour development after adminis-
tration of ATc or trastuzumab is reflected by the different fractions
of proliferating tumour cells.
Apoptosis as evidenced by the ratio of cytosolic to mitochon-
drial cytochrome c showed a moderate size increase 7h after ATc
administration (Table 1) similar to results obtained in a previous
study. Trastuzumab increased apoptosis 24h after administration
(Table 1). However, a decrease was observed after 72h. In
conclusion, apoptosis (Table 1) as well as proliferation (Figure 8)
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Figure 6 Influence of anhydrotetracycline (ATc) (A) and trastuzumab (B) on levels of phosphorylated and total Akt. Similarly, the influence of
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scorrespond to the differences in tumour development (Figure 5)
observed after administration of ATc and trastuzumab.
DISCUSSION
The emergence of trastuzumab has drastically changed the therapy
of breast cancer. Besides improvements in the therapy it led to the
concept that only a subgroup of tumours is ‘ERBB2 dependent’
(Weinstein, 2002; Baselga, 2006; Hengstler et al, 2006). This
underlines the need to direct trastuzumab only to this subset of
tumours whose growth depends on ERBB2 signalling. Trastuzu-
mab in tumours not (over)expressing ERBB2 is known to be
useless. On the other hand, not all breast carcinomas
overexpressing ERBB2 respond to trastuzumab. Although the
probability of remission is much better in Herceptest 3þ breast
carcinomas compared with tumours with lower levels of ERBB2,
still about 50% of Herceptest 3þ breast carcinomas are resistant
to trastuzumab. This may be explained by the fact that despite
overexpression of ERBB2, tumour growth may predominantly
depend on other oncogenes. Therefore, the ideal tumour for
trastuzumab therapy should not only overexpress but also be
‘ERBB2 dependent’ (Baselga, 2006). To our knowledge this concept
has not yet been challenged, probably due to the fact that it is
relatively difficult to determine to which degree tumour growth
depends on a particular oncogene.
We used a mouse tumour model where growth of the primary
tumours is 100% ERBB2 dependent. ERBB2 mRNA and protein
expression can efficiently be downregulated by administration of
anhydrotetracycline (ATc) to tumour-bearing mice. Downregula-
tion of ERBB2 leads to a rapid and macroscopically complete
tumour remission within 14 days. Tumour remission is accom-
panied by dephosphorylation of ERK1/2 and AKT/PKB, a strong
decrease of Ki-67-positive nuclei in tumour tissue and a moderate
increase in apoptosis as evidenced by the cytoplasmic fraction of
cytochrome c. These data demonstrate a strong ERBB2 dependence
of the tumours in our mouse model. Therefore, we initially
expected a high efficiency of trastuzumab. Surprisingly, trastuzu-
mab caused only a very weak delay in tumour growth, which is in
sharp contrast to the excellent efficiency of Atc-mediated ERBB2
downregulation. We used a route of administration and similar (or
even higher) doses of trastuzumab that have been shown to be
efficient in previous studies (Baselga et al, 1996; Cobleigh et al,
1999; Slamon et al, 2001). The interaction of trastuzumab with
ERBB2 in our mouse tumour model is illustrated by a strong
decrease in membrane localisation within 6h after administration
of trastuzumab. However, this did not lead to tumour remission. In
agreement with the very moderate influence on tumour growth
only a slight decrease in Ki 67 and a very weak increase in
cytoplasmic cytochrome c were observed. Recently, strong AKT/
PKB signalling has been shown to contribute to trastuzumab
resistance (Clark et al, 2002; Yakes et al, 2002; Tokunaga et al,
2006). Therefore, we analysed the influence of trastuzumab on the
levels of AKT/PKB phosphorylation. Interestingly, trastuzumab
caused a sharp 4–5-fold increase in phosphorylated AKT/PKB
already within 60–180min after administration of trastuzumab
(Figure 6B). Downregulation of ERBB2 by ATc did not cause such
a sharp increase but a moderate-size (1.8-fold) rise in AKT/PKB
phosphorylation not before 24h. Another response to trastuzumab
were increased AKT1 and AKT2 mRNA levels (3.5- and 5.3-fold,
respectively) already 60min after administration (Figure 6D)
leading to increased levels of AKT-protein (Figure 6B). The rapid
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Figure 7 Influence of trastuzumab (A) on levels of phosphorylated and total Erk. Representative immunoblot is shown (B). Data are mean values and s.e.
of 3–5 mice per group. Mean expression level of controls correspond to 100%.
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Figure 8 Influence of anhydrotetracycline (ATc) and trastuzumab on
proliferation, as evidenced by the fraction of Ki 67-positive tumour cells.
Data are mean values and s.e. of 3–5 mice per group.
Table 1 Time after onset of therapy
0h 24h 72h
ATc 0.05±0.02 0.07±0.03 0.20±0.06*
Trastuzumab 0.05±0.02 0.20±0.08* 0.11±0.03*
Influence of anhydrotetracycline (ATc) and trastuzumab on apoptosis in tumour
tissue as evidenced by the ratio of cytoplasmic and mitochondrial cytochrome c. Data
are mean values and s.d. of three mice per group. *Po0.05 compared to controls.
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may contribute to resistance against trastuzumab.
Recently, we have shown that dephosphorylation of ERK1/2 is
relevant for tumour remission after ERBB2-blocking therapy
(Hausherr et al, 2006). We have shown a strong dephosphorylation
of ERK1/2 after Atc-mediated downregulation of ERBB2 using the
same mouse tumour model as in the present work (Hausherr et al,
2006). In contrast to ATc, trastuzumab did not cause depho-
sphorylation of ERK1/2. Therefore, the lack in tumour remission
after trastuzumab administration may be explained by (i)
increased AKT/PKB phosphorylation, (ii) a rapid increase in
AKT/PKB mRNA and protein synthesis and (iii) a lack of ERK1/2
dephosphorylation.
In our study, a concentration of 40mgkg
 1 trastuzumab was
used for treatment of mice. To exclude a possible underdosing we
analysed membrane localisation of ERBB2. We observed a strong
decrease in ERBB2 membrane localisation during the first 24h
after Herceptin administration (Figures 3 and 4). Therefore, the
weak response of the tumour does not seem to be a result of
underdosing. It should be considered that 40mgkg
 1 is a very
high dose compared to doses used in other published studies. For
instance, Wang et al used 0.3mgkg
 1 and Scotti et al only 200mg
Herceptin per mouse. In both studies Herceptin clearly reduced
tumour growth in nude mice (Wang et al, 2005; Scotti et al, 2007).
It should also be considered that human ERBB2 was expressed in
our mouse tumour model (Schiffer et al, 2003), since Herceptin is
directed against the human oncogene.
The present results show that ‘ERBB2 dependence’ does not
automatically include ‘trastuzumab sensitivity’. It will be interest-
ing to analyse whether similar observations can be made in human
tumour cells, whereby analysis of functional ‘ERBB2 dependence’
will be more difficult compared to the NIH3T3-HER2 model.
Another feature of our mouse model is the compromised immune
system, since tumours were induced in nude mice. Therefore,
antibody-mediated cytotoxicity due to the immune system will not
be observed in the NIH3T3-HER2 mouse model.
In conclusion, we have demonstrated that ‘ERBB2 dependence’
does not necessarily include sensitivity to trastuzumab, even if
cells overexpress ERBB2 and if trastuzumab induces internalisa-
tion of the ERBB2 receptor.
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